Physician profile
Theresa J Watts
NPI 1225318645
$645,478.29
in general payments reported to CMS, 2019-2025
18 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82K · 2022: $119K · 2023: $155K · 2024: $141K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $359K · Travel and Lodging: $67K · Food and Beverage: $18K · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $358,775.00 |
| Travel and Lodging | $67,278.99 |
| Food and Beverage | $17,906.27 |
| Education | $127.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638,270.02 | 2021-2025 | |
| Allergan, INC. | $1,650.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,058.21 | 2021-2025 | Caplyta |
| Alkermes, INC. | $711.19 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $707.22 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $700.01 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $593.27 | 2021-2024 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $584.38 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Sunovion Pharmaceuticals INC. | $306.03 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $247.80 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $200.13 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $130.26 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $109.26 | 2024-2025 | Cobenfy |
| Indivior INC. | $64.92 | 2021-2023 | Perseris |
| Lundbeck LLC | $56.79 | 2021-2024 | Abilify Maintena, Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $56.77 | 2021-2023 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.70 | 2024 | |
| Braeburn INC. | $15.33 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.